Back to Journals » Drug Design, Development and Therapy » Volume 4

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Total article views   Abstract views HTML views PDF downloads Totals
15,935 Dovepress* 13,965 543+ 1,905 14,508
PubMed Central* 20 1,407 554 1,427
Totals 13,985 1,950 2,459 15,935
*Since 15 November 2010
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 0 4

View citations on PubMed Central and Google Scholar